News & Media

    Patients Treating Flares of Osteoarthritis with CL-108 Experienced Improvements in Activities of Daily Living Under Actual Conditions of Use

    Abstract not published in abstract book

    What is the likelihood of opioid-induced nausea and vomiting (OINV) in patients who by history are assumed to be not at risk of developing OINV?

    Abstract not published in abstract book

    Prophylactic Antiemetic Use Reduces Opioid Induced Nausea and Vomiting and Improves Patient Recovery in the Outpatient Setting

    Oak Y, Gregorian R, Kwong W, Kane A, Zou P, Marrett E. J Manag Care Pharm. 2017:23:S91.

    Health Care Utilization and Costs Associated with Nausea and Vomiting in Patients Receiving Oral Immediate-Release Opioids for Outpatient Acute Pain Management

    Marrett E, Kwong WJ, Frech F, Qian C. Pain Ther. 2016;5:215-226.

    Clinically Meaningful Pain Relief in Patients with Moderate to Severe Acute Pain Treated with CL-108

    Published abstract book not available

    The incidence of opioid-induced nausea and vomiting (OINV) in patients who by history are assumed to be not at risk of developing OINV

    Published abstract book not available

    Patients Treating Flares of Osteoarthritis with CL-108 Experienced Improvements in Activities of Daily Living Under Actual Conditions of Use

    Published abstract book not available

    Results from Using the Nausea Intensity Scale: The Severity Of Nausea is Significantly Reduced by CL-108 Compared with a Standard Hydrocodone/ Acetaminophen Analgesic When Used to Treat Moderate-To-Severe Pain

    Published abstract book not available

    No evidence of increased abuse potential of CL-108, a bi-layered tablet containing hydrocodone/acetaminophen/promethazine, in recreational opioid users

    Shram M, Levy-Cooperman N, Webster L. (2016) PAINWeek Abstract Book 2016, Postgraduate Medicine, 128:sup2, 84

    Actual-Use Study of CL-108 for the treatment of flares of osteoarthritis of the knee or hip

    Aazami H, Glover RM, Kivitz AJ, Oliver D, Ricci DR, Surowitz R, Schachtel B. (2016) PAINWeek Abstract Book 2016, Postgraduate Medicine, 128:sup2, 79.

    The Efficacy of CL-108 in Preventing Opioid-Induced Nausea and Vomiting (OINV)

    Daniels SE, Richardson SF, Patrick K, Royall SP, Schachtel E, Lorton MB, Zhang B, Cho S, Schachtel BP. (2016) PAINWeek Abstract Book 2016, Postgraduate Medicine, 128:sup2, 79.

    The Impact of Nausea on Pain and its Relief

    Bender R, Schachtel B, Revicki D, Rentz A, Kwong J, Marrett E. (2016) PAINWeek Abstract Book 2016, Postgraduate Medicine, 128:sup2, 9.

    Use of the Qualities of Pain Index (QPI) to demonstrate beneficial effects on affective and sensory qualities of pain

    Schachtel B, Hersh E, Zuniga J, Daniels S, Muse D, Patrick K, Oreadi D, Bennett J, Schachtel E, Papas A. (2016) PAINWeek Abstract Book 2016, Postgraduate Medicine, 128:sup2, 104.

    Patients Treated with CL-108 Over a 5-day Post-Operative Period Use Less Antiemetic Medication for Opioid-Induced Nausea and Vomiting (OINV) than Patients Treated with Standard Hydrocodone/Acetaminophen

    Hersh EV, Schachtel B. (2016) PAINWeek Abstract Book 2016, Postgraduate Medicine, 128:sup2, 41.

    Objective evidence of the efficacy of CL-108 compared to standard hydrocodone 7.5 mg/ acetaminophen 325 mg in preventing Opioid-Induced Nausea and Vomiting (OINV)

    Hersh EV, Schachtel B, Kozarek WJ, Schachtel E. (2016) PAINWeek Abstract Book 2016, Postgraduate Medicine, 128:sup2, 80.

    Safety and Effectiveness of CL-108 for the Treatment of Moderate-to-Severe Pain Associated with Flares of Osteoarthritis of the Knee or Hip

    Schachtel B, Marino M, Lazar J, Aazami H, Burnette M, Kivitiz A, Lewis K, Lorton MB, McIlwain H, Munir M, Oliver D, Poland S, Ricci D, Schachtel E, Tseytlin L. Pain Med. 2016;17(2):429.

    CL-108 Reduces the Use of Rescue Antiemetic Medications for Opioid-Induced Nausea and Vomiting

    Hersh E, Marino M, Schachtel B. Pain Med. 2016;17(2):423.

    No evidence of increased abuse potential of CL-108 a bilayered tablet containing hydrocodone/ acetaminophen/promethazine, in recreational opioid users

    Levy-Cooperman N, Shram M, Webster LR.

    Healthcare Costs Associated with Nausea and Vomiting in Patients Receiving Oral Immediate-Release Opioids for the Management of Acute Pain in the Outpatient Setting

    Marrett E, Frech F, Zhang Q, Qian C. JMCP. 2016;22:S114.

    Opioid-Induced Nausea and Vomiting (OINV) in Post-Operative Patients: A Comparison of CL-108 to Hydrocodone 7.5 mg/Acetaminophen 325 mg

    Richardson SF, Patrick K, Daniels SE, Royall SP, Schachtel E, Zhang B, Marino M, Schachtel B. J Pain. 2016;17(4):S83.

    Efficacy of CL-108 compared to hydrocodone 7.5 mg/acetaminophen 325 mg in preventing vomiting and the use of anti-emetics, Opioid-Induced Nausea and Vomiting (OINV)

    Hersh E, Schachtel B, Kozarek W, E Schachtel, Marino M. J Pain. 2016;17(4):S82

    What is the incidence of opioid-induced nausea and vomiting in patients who do not have immediate post-operative nausea or vomiting?

    Schachtel B, Marino M, Kozarek W, Schachtel E, Hersh E. (2015) PAINWeek Abstract Book 2015, Postgraduate Medicine, 127:sup1, S83.

    NEED WORD DOC: The incidence of opioid-induced nausea and vomiting (OINV) in patients with a history that is only suggestive of developing OINV
    Opioid-Induced Nausea and Vomiting (OINV) in patients without immediate post-op nausea/vomiting

    Hersh E, Kozarek W, Marino M, Schachtel B. Opioid-Induced Nausea and Vomiting (OINV) in patients without immediate post-op nausea/vomiting. J Pain. 2015;16(4):S80.

    Affective and sensory qualities of pain complement evaluative measures of opioid analgesia: results from the Qualities of Dental Pain Index (QDPI)

    Schachtel B, Hersh E, Papas A, Daniels S, Muse D, Patrick K, Bennett J, Schachtel E, Marino M, Zuniga J. J Pain. 2015;16(4):S7.

    What is the likelihood of opioid-induced nausea and vomiting (OINV) in patients with a history that is only suggestive of OINV?

    Hersh E, Papas A, Zuniga J, Daniels S, Muse D, Patrick K, Bennett J, Schachtel E, Marino M, Schachtel B. J Pain. 2015;16(4):S16.

    Safety and efficacy of CL-108 for moderate-to-severe acute pain with reduction of opioid-induced nausea and vomiting

    Hersh E, Schachtel B, Daniels S, Muse D, Patrick K, Zuniga J, Bennett J, Schachtel E, Papas A. Poster presented at: Pain Week 2014; September 2-6, 2014; Las Vegas, NV.

    Demonstration of the safety and efficacy of CL-108 for moderate-to-severe pain with reduction of opioid-induced nausea and vomiting

    Schachtel B, Younes N, Zhou J, Schachtel E, Hersh E. Demonstration of the safety and efficacy of CL-108 for moderate-to-severe pain with reduction of opioid-induced nausea and vomiting. J Pain 2014;15(4): S81.